Jakob Stensballe1, Sisse R Ostrowski, Pär I Johansson. 1. aSection for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital, Rigshospitalet, DenmarkbDepartment of Anaesthesia, Centre of Head and Orthopedics, Copenhagen University Hospital, Rigshospitalet, DenmarkcDepartment of Surgery, Division of Acute Care Surgery, Centre for Translational Injury Research (CeTIR), University of Texas Medical School at Houston, Texas, USAdCentre for Systems Biology, The School of Engineering and Natural Sciences, University of Iceland, Iceland.
Abstract
PURPOSE OF REVIEW: To discuss the recent developments in and evolvement of next generation haemostatic resuscitation in bleeding trauma. RECENT FINDINGS: Mortality from major trauma is a worldwide problem, and massive haemorrhage remains a major cause of potentially preventable deaths. Development of coagulopathy further increases trauma mortality emphasizing that coagulopathy is a key target in the phase of bleeding. The pathophysiology of coagulopathy in trauma reflects at least three distinct mechanisms that may be present isolated or coexist: acute traumatic coagulopathy, coagulopathy associated with the lethal triad, and consumptive coagulopathy. The concepts of 'damage control surgery' and 'damage control resuscitation' have been developed to ensure early control of bleeding and coagulopathy to improve outcome in bleeding trauma. Haemostatic resuscitation aims at controlling coagulopathy and consists of a ratio driven strategy aiming at 1 : 1 : 1, using tranexamic acid according to CRASH-2, and applying haemostatic monitoring enabling a switch to a goal-directed approach when bleeding slows. Haemostatic resuscitation is the mainstay of trauma resuscitation and is associated with improved survival. SUMMARY: The next generation of haemostatic resuscitation aims at applying a ratio 1 : 1 : 1 driven strategy while using antifibrinolytics, haemostatic monitoring and avoiding critical fibrinogen deficiency by substitution.
PURPOSE OF REVIEW: To discuss the recent developments in and evolvement of next generation haemostatic resuscitation in bleeding trauma. RECENT FINDINGS: Mortality from major trauma is a worldwide problem, and massive haemorrhage remains a major cause of potentially preventable deaths. Development of coagulopathy further increases trauma mortality emphasizing that coagulopathy is a key target in the phase of bleeding. The pathophysiology of coagulopathy in trauma reflects at least three distinct mechanisms that may be present isolated or coexist: acute traumatic coagulopathy, coagulopathy associated with the lethal triad, and consumptive coagulopathy. The concepts of 'damage control surgery' and 'damage control resuscitation' have been developed to ensure early control of bleeding and coagulopathy to improve outcome in bleeding trauma. Haemostatic resuscitation aims at controlling coagulopathy and consists of a ratio driven strategy aiming at 1 : 1 : 1, using tranexamic acid according to CRASH-2, and applying haemostatic monitoring enabling a switch to a goal-directed approach when bleeding slows. Haemostatic resuscitation is the mainstay of trauma resuscitation and is associated with improved survival. SUMMARY: The next generation of haemostatic resuscitation aims at applying a ratio 1 : 1 : 1 driven strategy while using antifibrinolytics, haemostatic monitoring and avoiding critical fibrinogen deficiency by substitution.
Authors: Bellal Joseph; Muhammad Zeeshan; Joseph V Sakran; Mohammad Hamidi; Narong Kulvatunyou; Muhammad Khan; Terence O'Keeffe; Peter Rhee Journal: JAMA Surg Date: 2019-06-01 Impact factor: 14.766
Authors: Marco Tartaglione; Luca Carenzo; Lorenzo Gamberini; Cristian Lupi; Aimone Giugni; Carlo Alberto Mazzoli; Valentina Chiarini; Silvia Cavagna; Davide Allegri; John B Holcomb; David Lockey; Giovanni Sbrana; Giovanni Gordini; Carlo Coniglio Journal: BMJ Open Date: 2022-05-30 Impact factor: 3.006
Authors: Jessica E van der Meij; Leo M G Geeraedts; Saskia J M Kamphuis; Nimmi Kumar; Tony Greenfield; Geoff Tweeddale; David Rosenfeld; Scott K D'Amours Journal: ANZ J Surg Date: 2019-09-09 Impact factor: 1.872
Authors: Nicole P Juffermans; Mathijs R Wirtz; Kirsten Balvers; Kjersti Baksaas-Aasen; Susan van Dieren; Christine Gaarder; Paul A Naess; Simon Stanworth; Pär I Johansson; Jakob Stensballe; Marc Maegele; J C Goslings; Karim Brohi Journal: J Thromb Haemost Date: 2019-02-17 Impact factor: 5.824